Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech

Regulatory News:

At today’s Annual General Shareholders' Meeting (AGM) of Sartorius Stedim Biotech S.A. in Aubagne, France, shareholders approved the Board of Directors’ proposals by a large majority.

The AGM thus passed the resolution to pay dividends of €1.30 net per share for fiscal 2014, up from €1.20 a year earlier. The total profit distributed will therefore rise from €18.4 million to €20.0 million.

The AGM elected new non-executive members to the Board of Directors: Anne Marie Graffin, Managing Director of SMAG Consulting SARL, and Susan Dexter, Principal Consultant of the Latham Biopharm Group. As a result, the number of Board members has increased from eight to ten. In addition, Oscar-Werner Reif’s term on the Board was renewed following his initial appointment in 2009. As Executive Vice President, he also manages the Group’s global Research & Development unit.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech (Paris:DIM) is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.

Petra Kirchhoff; Vice President of Corporate CommunicationsSartorius Corporate Administration GmbHPhone: +49(0)551.308.1686;Fax: [phone]E-mail: [e-mail];www.sartorius-stedim.com